Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
February 29, 2024 09:15 ET
|
Virios Therapeutics
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
February 28, 2024 09:15 ET
|
Virios Therapeutics
ATLANTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...
Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
January 22, 2024 09:00 ET
|
Virios Therapeutics
- Placebo-Controlled Clinical Proof of Concept Data Expected in Mid-2024 -- Targeting Initiation of IMC-2 Phase 2 program in 2H 2024 - ATLANTA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Virios...
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
January 02, 2024 07:05 ET
|
Virios Therapeutics
ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on developing novel antiviral therapies to...
Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023 07:05 ET
|
Virios Therapeutics
- Conference Call Today at 8:30 a.m. ET - ATLANTA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on...
Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
November 06, 2023 07:05 ET
|
Virios Therapeutics
ATLANTA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral...
Virios Therapeutics Announces Termination of At-The-Market Sales Agreement
September 18, 2023 07:05 ET
|
Virios Therapeutics
ATLANTA, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...
Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023
September 12, 2023 07:05 ET
|
Virios Therapeutics
ATLANTA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...
FMW Media Works Corp. Announces its “Exploring The Block” TV Show with Two New Featured Clients, Shivom (OMX) and PascalCoin (PASC)
November 09, 2018 16:45 ET
|
NEW TO THE STREET
NEW YORK, Nov. 09, 2018 (GLOBE NEWSWIRE) -- FMW Media Works Corp. announces two new featured clients, Shivom and PascalCoin, both appearing on “Exploring The Block” TV. On November 28, 2018,...